Clinical trial · Interventional
RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
Phase II/III Randomized Clinical Trial of Radiosensitivity-Assisted Personalized Adaptive RadioTherapy (RAPART) in Locally Advanced Non-small Cell Lung Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase II/III randomized clinical trial of Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology (RAPART) in locally advanced non-small cell lung cancer patients. The main objective is to test the overall improvement of overall survival (OS), progression free survival (PFS), and local progression free survival (LPFS) of unresectable stage III NSCLC under standard and non-standard mixed treatment conditions compared to conventional 60Gy radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conventional radiotherapy | Radiation | — | UNRESOLVED |
| Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology（RAPART)） | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Experiment
- description
- RAPART technology
- interventionNames
- Radiation: Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology（RAPART)）
- type
- ACTIVE_COMPARATOR
- label
- conventional radiotherapy
- description
- conventional radiotherapy 2Gy/F
- interventionNames
- Radiation: Conventional radiotherapy
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult research participants, aged over 18 years old; * Non small cell lung cancer that requires pathological confirmation; * All stage 3 unresectable non-small cell lung cancer, including stage correction after MDT and stage downgrading after treatment (4 → 3), and stage upregulation due to disease progression (2 → 3); * ECOG physical condition is 0-2; * In addition to study participants who have not received any treatment, study participants who have undergone surgery, chemotherapy, immunotherapy, and targeted therapy are also eligible for enrollment. Exclusion Criteria: * Prisoners who are not convenient for close clinical follow-up; * Study participants with contraindications to radiation therapy.
References
Publications (0)
Data not yet available